Supraventricular Tachycardia
Cardiovascular 1 original drugsCardiovascular indication. Supraventricular Tachycardia has 1 FDA-approved novel treatment, led by AOP HLTH US across 8 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Supraventricular Tachycardia Market Leaders
Companies with the most FDA-approved novel Supraventricular Tachycardia drugs.
Supraventricular Tachycardia Clinical Pipeline by Phase
7 industry-sponsored trials across 6 sponsors
Novel Supraventricular Tachycardia Drugs by Company (New molecular entities)
1 company has an FDA-approved novel drug for Supraventricular Tachycardia.
Reformulations (6 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Supraventricular Tachycardia Drug Targets
Molecular targets of approved and investigational Supraventricular Tachycardia drugs — 8 targets tracked.
Generic Drugs (4 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs